2010 AnnuAl REpoRT - Ciberdem

Metabolic disease and cardiovascular risk
Hospital de la Santa Creu i Sant Pau, Servei de Bioquímica i Endocrinologia, Barcelona
www.santpau.cat
Principal Investigator Francisco Blanco Vaca fblancova@santpau.cat Associate researchers Joan Carles Escolà, Jesús María Martín,
Antonio Pérez, Josep Julve Postdoctoral fellows Gemma Llaverias, Juan Antonio Sánchez Lab technicians Carme Mayoral, Cristina
Muñoz, Rosa Roig, David Santos
Total IF: 15.433
Publications: 3, 1 of them in the first decile and 2 in the first quartile
With other CIBERDEM groups: 2
With other international groups: 1
Research grants: 8
European projects: 1
National projects: 4
Autonomous Community projects: 1
Private funds: 2
Scientific collaborations within CIBERDEM: 3
Clinical trials: 3
Keywords
Genetics type 2 diabetes. Lipid metabolism. Lipids,
lipoproteins. Metabolic syndrome. Pathogenic mechanisms.
Main lines of research
-Antiinflammatory actions of HDL: effects on diabetes
mellitus and atherothrombotic cardiovascular disease.
-Genetics of complex metabolic diseases: hyperlipidaemia,
type 2 diabetes and hyperhomocysteinaemia.
-Development of experimental-biochemistry and molecularbiology
techniques and their application to clinical
laboratory practice (innovation).
Publications*
Original articles
Cyclooxygenase 2 inhibition exacerbates palmitate-induced
inflammation and insulin resistance in skeletal muscle cells
Coll T, Palomer X, Blanco-Vaca F, Escolà-Gil JC, Sánchez
RM, Laguna JC, Vázquez-Carrera M
Endocrinology, 151, 537-548 (2010)
IF: 4.752 first quartile. With other CIBERDEM groups:
M Vázquez Carrera
Disodium ascorbyl phytostanol phosphate (FM-VP4), a
modified phytostanol, is a highly active hypocholesterolaemic
*Only those published in 2010, with CIBERDEM listed among the affiliations, which are related to CIBERDEM’s field of research and are
located in the first or second quartile of their subject category are included.
56 CibeRdem